Long-term follow-up after receiving ST-920
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study checks how people are doing long after they previously received ST-920 in an earlier trial. It may help researchers understand long-term safety and outcomes from that treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously received ST-920 in an earlier (parent) trial
- You must have consented to join this long-term follow-up study
- You will participate only if you are already enrolled in the parent trial’s ST-920 group
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial gives patients with Fabry disease who took part in a previous study the chance to continue receiving the study treatment, lucerastat, after that study ends. It aims to provide uninterrupted care while longer-term safety and effects are monitored.
This study looks at how well available Fabry disease treatments (like migalastat or ERT) work over time in real life. It may help doctors understand who benefits most from these medicines.
This trial tests if enzyme replacement therapy works well and is safe for Fabry disease. It is for people who are already prescribed this treatment.
This trial tests if the oral drug migalastat is safe and works for children aged 2 to under 12 with a specific type of Fabry disease. It may be an option if your child has not been on enzyme therapy recently and has a compatible gene variant.
This Phase 1/2 study tests how safe and potentially effective 4D-310 is for adults with Fabry disease who have heart involvement. It may help people who can’t tolerate standard treatments like enzyme replacement therapy (ERT) or migalastat, or who still have disease progression.
This study follows pregnant and breastfeeding women with Fabry disease (and their infants) to better understand what happens during pregnancy and early life. You may or may not be taking migalastat, and the goal is to gather real-world information that could help future care.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.